Birgitte Rønø

Birgitte Rønø, Chief Scientific Officer

Birgitte Rønø, PhD, joined us as Senior Director, Immuno-Oncology in September 2017. Dr. Rønø has developed and led our pre-clinical and early clinical oncology pipeline. In September 2021, Dr. Rønø was appointed Chief Scientific Officer. Dr Rønø has more than 15 years’ experience in biopharmaceutical drug discovery from academia and industry. Prior to joining Evaxion, Dr. Rønø served as a specialist, team leader and project manager at Novo Nordisk, from 2013-2017, where she was leading early drug discovery projects, evaluating in-licensing opportunities, and supporting drug development projects with pre-clinical and biomarker expertise. Dr. Rønø holds a bachelor’s degree in medicine and a master’s degree in human biology, both from the University of Copenhagen, Denmark. Dr. Rønø received her Ph.D. in experimental oncology and immunology from National Institutes of Health, Bethesda, USA and Copenhagen University Hospital, Denmark.